Mebufotenin

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameMebufotenin
Drug Alias Name5 Methoxy N N dimethyltryptamine5 Methoxy N,N DimethyltryptamineMebufotenin for inhalation administration5-MeO-DMTGH-001 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 1b (5-HT1b) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorSerotonin 1b (5-HT1b) receptor
Therapy Area/IndicationsBipolar II DisorderStress Disorders, Post-TraumaticCognitive Dysfunction +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGH Research Ireland Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUsona Institute IncBiomind Labs IncGH Research Ireland Ltd +[4] 
Inactive CompaniesJohns Hopkins University
Active IndicationsCognitive DysfunctionDepressive Disorder, Treatment-ResistantDepressive Disorder, Major +[6] 
Inactive IndicationsBipolar II DisorderStress Disorders, Post-TraumaticDepression, Postpartum +[5] 

Other Information

ATC CodeN/A
Related LinksN/A